Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Pharmos (PARS) -- Ignore unavailable to you. Want to Upgrade?

To: rjk01 who wrote (1342)	12/5/2004 10:55:02 AM
From: NeuroInvestment	Read Replies (1) \| Respond to of 1386

Aviv sold around 12% of his holdings. It was clearly a hedge against unexpected failure--he is 67, and while his insensitivity to shareholder impact is becoming legion--if I were 67, I wouldnt put most of my retirement funds on a Phase III single trial either. Riesenfeld sold 16% due to a personal financial situation. The timing was obnoxious. But I firmly believe it does not reflect a leak--though it does provide confirmation (as if any rational observer needed any) that one can never assume that a neuroprotectant Phase III is a (and how I have come to loathe this phrase) 'slam dunk.' Harry NeuroInvestment